Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
19
TOVX Quote, Financials, Valuation and Earnings
Last price:
$0.19
Seasonality move
:
18281.59%
Day range:
$0.19 - $0.20
52-week range:
$0.17 - $2.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.33x
P/B ratio:
1.02x
Volume:
6.6M
Avg. volume:
2.7M
1-year change:
-83.08%
Market cap:
$6.8M
Revenue:
--
EPS (TTM):
-$5.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-- | -$0.32 | -100% | -12.44% | $5.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.58 | $5.00 | $49.3M | -- | $0.00 | 0% | 547.66x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.57 | $0.85 | $575.9M | 7.68x | $0.80 | 0% | 8.88x |
|
NNVC
NanoViricides, Inc.
|
$1.20 | $6.50 | $21.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $682.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
7.66% | -2.165 | 2.29% | 7.81x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-$116K | -$5.7M | -126.64% | -133.63% | -6324.44% | -$6.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Theriva Biologics, Inc. vs. Competitors
-
Which has Higher Returns TOVX or ATNM?
Actinium Pharmaceuticals, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of -5701.11%. Theriva Biologics, Inc.'s return on equity of -171.04% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M ATNMActinium Pharmaceuticals, Inc.-128.89% -$0.16 $14.9M -
What do Analysts Say About TOVX or ATNM?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3349.98%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 212.5%. Given that Theriva Biologics, Inc. has higher upside potential than Actinium Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Actinium Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 ATNMActinium Pharmaceuticals, Inc.3 1 0 -
Is TOVX or ATNM More Risky?
Theriva Biologics, Inc. has a beta of 0.342, which suggesting that the stock is 65.818% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.367, suggesting its less volatile than the S&P 500 by 136.662%.
-
Which is a Better Dividend Stock TOVX or ATNM?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or ATNM?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Theriva Biologics, Inc.'s net income of -$4.4M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 547.66x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M ATNMActinium Pharmaceuticals, Inc.547.66x -- $90K -$5.1M
-
Which has Higher Returns TOVX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of -255.85%. Theriva Biologics, Inc.'s return on equity of -171.04% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TOVX or NBY?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3349.98%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Theriva Biologics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TOVX or NBY More Risky?
Theriva Biologics, Inc. has a beta of 0.342, which suggesting that the stock is 65.818% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock TOVX or NBY?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or NBY?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Theriva Biologics, Inc.'s net income of -$4.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M
-
Which has Higher Returns TOVX or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of --. Theriva Biologics, Inc.'s return on equity of -171.04% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About TOVX or NNVC?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3349.98%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 441.67%. Given that Theriva Biologics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Theriva Biologics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 NNVCNanoViricides, Inc.1 0 0 -
Is TOVX or NNVC More Risky?
Theriva Biologics, Inc. has a beta of 0.342, which suggesting that the stock is 65.818% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock TOVX or NNVC?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or NNVC?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Theriva Biologics, Inc.'s net income of -$4.4M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns TOVX or OGEN?
Oragenics, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of --. Theriva Biologics, Inc.'s return on equity of -171.04% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About TOVX or OGEN?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3349.98%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 141.11%. Given that Theriva Biologics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 OGENOragenics, Inc.1 0 0 -
Is TOVX or OGEN More Risky?
Theriva Biologics, Inc. has a beta of 0.342, which suggesting that the stock is 65.818% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock TOVX or OGEN?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or OGEN?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Theriva Biologics, Inc.'s net income of -$4.4M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns TOVX or PTN?
Palatin Technologies has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of --. Theriva Biologics, Inc.'s return on equity of -171.04% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About TOVX or PTN?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3349.98%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Theriva Biologics, Inc., analysts believe Palatin Technologies is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 PTNPalatin Technologies0 0 0 -
Is TOVX or PTN More Risky?
Theriva Biologics, Inc. has a beta of 0.342, which suggesting that the stock is 65.818% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock TOVX or PTN?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or PTN?
Theriva Biologics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Theriva Biologics, Inc.'s net income of -$4.4M is higher than Palatin Technologies's net income of --. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
